The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab
Status:
RECRUITING
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The goal of this open-label, single-blind, controlled-trial is to evaluate brain changes evaluated with diffusion Magnetic Resonance Imaging (MRI) and functional MRI in patients with high-frequency episodic migraine and chronic migraine that will be treated with Fremanezumab, 12 weeks after the treatment onset, compared with the baseline.
Type of study: Phase IV clinical trial Participant population: high-frequency episodic migraine and chronic migraine. Participants will be treated with Fremanezumab.
Phase:
PHASE4
Details
Lead Sponsor:
Hospital Clínico Universitario de Valladolid
Collaborators:
Complejo Asistencial Universitario de Palencia Complejo Público Asistencial de Zamora University of Valladolid